|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAP3K8 |
 Gene summary |
| Basic gene Info. | Gene symbol | MAP3K8 |
| Gene name | mitogen-activated protein kinase kinase kinase 8 | |
| Synonyms | COT|EST|ESTF|MEKK8|TPL2|Tpl-2|c-COT | |
| Cytomap | UCSC genome browser: 10p11.23 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001244134.1, NM_005204.3, | |
| Description | Ewing sarcoma transformantcot (cancer Osaka thyroid) oncogeneproto-oncogene c-Cotproto-oncogene serine/threoine protein kinasetumor progression locus 2 | |
| Modification date | 20141222 | |
| dbXrefs | MIM : 191195 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000107968 | ||
| HPRD : 01863 | ||
| Vega : OTTHUMG00000017889 | ||
| Protein | UniProt: P41279 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAP3K8 | |
| BioGPS: 1326 | ||
| Pathway | NCI Pathway Interaction Database: MAP3K8 | |
| KEGG: MAP3K8 | ||
| REACTOME: MAP3K8 | ||
| Pathway Commons: MAP3K8 | ||
| Context | iHOP: MAP3K8 | |
| ligand binding site mutation search in PubMed: MAP3K8 | ||
| UCL Cancer Institute: MAP3K8 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for MAP3K8 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A165 | A165V | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAP3K8 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A165 | A165V | -0.55567537 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAP3K8 from PDB |
| Top |
| Differential gene expression and gene-gene network for MAP3K8 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAP3K8 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0024121 | Lung Neoplasms | 2 | AlteredExpression, Biomarker |
| umls:C0151744 | Myocardial Ischemia | 1 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAP3K8 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAP3K8 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | 49B | 5-[2-AMINO-5-(QUINOLIN-3-YL)PYRIDIN-3-YL]-1,3,4- OXADIAZOLE-2(3H)-THIONE | 4y83 | A | A165 | 49B | 5-[2-AMINO-5-(QUINOLIN-3-YL)PYRIDIN-3-YL]-1,3,4- OXADIAZOLE-2(3H)-THIONE | 4y83 | B | A165 | 49B | 5-[2-AMINO-5-(QUINOLIN-3-YL)PYRIDIN-3-YL]-1,3,4- OXADIAZOLE-2(3H)-THIONE | 4y83 | C | A165 | 499 | 5-[5-(1H-INDOL-3-YL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]-1, 3,4-OXADIAZOL-2-AMINE | 4y85 | A | A165 | 499 | 5-[5-(1H-INDOL-3-YL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]-1, 3,4-OXADIAZOL-2-AMINE | 4y85 | B | A165 | 499 | 5-[5-(1H-INDOL-3-YL)-1H-PYRROLO[2,3-B]PYRIDIN-3-YL]-1, 3,4-OXADIAZOL-2-AMINE | 4y85 | C | A165 |
| Top |
| Conservation information for LBS of MAP3K8 |
| Multiple alignments for P41279 in multiple species |
| LBS | AA sequence | # species | Species | A165 | TKKRMACKLIP | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | D270 | KAVLVDFGLSV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E208 | VHLFMEAGEGG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | E217 | GGSVLEKLESC | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | F143 | NIGSDFIPRGA | 1 | Homo sapiens | F143 | NIGSGFVPRGA | 1 | Mus musculus | F143 | SIGSGFVPRGA | 1 | Rattus norvegicus | G147 | GFVPRGAFGKV | 2 | Mus musculus, Rattus norvegicus | G147 | DFIPRGAFGKV | 1 | Homo sapiens | G210 | LFMEAGEGGSV | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | G213 | EAGEGGSVLEK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | I144 | IGSGFVPRGAF | 2 | Mus musculus, Rattus norvegicus | I144 | IGSDFIPRGAF | 1 | Homo sapiens | K133 | LLIPWKLTYRN | 1 | Homo sapiens | K133 | LLVPWKLTYRN | 1 | Mus musculus | K133 | LLVPWKLTYRS | 1 | Rattus norvegicus | K167 | KRMACKLIPVD | 2 | Homo sapiens, Rattus norvegicus | K167 | KRMACKLIPID | 1 | Mus musculus | L134 | LIPWKLTYRNI | 1 | Homo sapiens | L134 | LVPWKLTYRNI | 1 | Mus musculus | L134 | LVPWKLTYRSI | 1 | Rattus norvegicus | M207 | TVHLFMEAGEG | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | P145 | GSGFVPRGAFG | 2 | Mus musculus, Rattus norvegicus | P145 | GSDFIPRGAFG | 1 | Homo sapiens | R146 | SGFVPRGAFGK | 2 | Mus musculus, Rattus norvegicus | R146 | SDFIPRGAFGK | 1 | Homo sapiens | S214 | AGEGGSVLEKL | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V152 | GAFGKVYLAQD | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V260 | KPSNIVFMSTK | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | V269 | TKAVLVDFGLS | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | W132 | VLLVPWKLTYR | 2 | Mus musculus, Rattus norvegicus | W132 | VLLIPWKLTYR | 1 | Homo sapiens |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |